vs
Side-by-side financial comparison of 4D Molecular Therapeutics, Inc. (FDMT) and Sezzle Inc. (SEZL). Click either name above to swap in a different company.
Sezzle Inc. is the larger business by last-quarter revenue ($135.5M vs $85.1M, roughly 1.6× 4D Molecular Therapeutics, Inc.). Sezzle Inc. runs the higher net margin — 37.9% vs 22.8%, a 15.1% gap on every dollar of revenue. On growth, 4D Molecular Therapeutics, Inc. posted the faster year-over-year revenue change (8508900.0% vs 29.2%). Over the past eight quarters, 4D Molecular Therapeutics, Inc.'s revenue compounded faster (5412.6% CAGR vs 111.9%).
4D Molecular Therapeutics is a clinical-stage biotechnology company specializing in the research and development of targeted adeno-associated virus (AAV) gene therapies. Its core product candidates address unmet medical needs in ophthalmology, cardiology, and pulmonary disease segments, serving global patient populations with rare and common hard-to-treat conditions.
Sezzle is a publicly traded financial technology company headquartered in Minneapolis, U.S, with operations in the United States and Canada. The company provides an alternative payment platform offering interest-free installment plans at selected online stores. As of June 2021, the Sezzle platform had over 10 million user sign-ups and over 48,000 participating merchants.
FDMT vs SEZL — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $85.1M | $135.5M |
| Net Profit | $19.4M | $51.3M |
| Gross Margin | — | — |
| Operating Margin | 17.3% | 50.9% |
| Net Margin | 22.8% | 37.9% |
| Revenue YoY | 8508900.0% | 29.2% |
| Net Profit YoY | 139.1% | 41.9% |
| EPS (diluted) | $0.43 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $135.5M | ||
| Q4 25 | $85.1M | $78.2M | ||
| Q3 25 | $90.0K | $57.5M | ||
| Q2 25 | $15.0K | $52.0M | ||
| Q1 25 | $14.0K | $48.2M | ||
| Q4 24 | $1.0K | $48.4M | ||
| Q3 24 | $3.0K | $35.6M | ||
| Q2 24 | $5.0K | $30.2M |
| Q1 26 | — | $51.3M | ||
| Q4 25 | $19.4M | $42.7M | ||
| Q3 25 | $-56.9M | $26.7M | ||
| Q2 25 | $-54.7M | $27.6M | ||
| Q1 25 | $-48.0M | $36.2M | ||
| Q4 24 | — | $25.4M | ||
| Q3 24 | $-43.8M | $15.4M | ||
| Q2 24 | $-35.0M | $29.7M |
| Q1 26 | — | 50.9% | ||
| Q4 25 | 17.3% | 70.6% | ||
| Q3 25 | -67983.3% | 61.9% | ||
| Q2 25 | -396373.3% | 69.4% | ||
| Q1 25 | -383007.1% | — | ||
| Q4 24 | — | 63.8% | ||
| Q3 24 | -1704400.0% | 58.6% | ||
| Q2 24 | -849120.0% | 55.3% |
| Q1 26 | — | 37.9% | ||
| Q4 25 | 22.8% | 54.6% | ||
| Q3 25 | -63195.6% | 46.4% | ||
| Q2 25 | -364386.7% | 53.1% | ||
| Q1 25 | -342657.1% | 75.1% | ||
| Q4 24 | — | 52.4% | ||
| Q3 24 | -1461433.3% | 43.4% | ||
| Q2 24 | -699060.0% | 98.4% |
| Q1 26 | — | — | ||
| Q4 25 | $0.43 | $1.19 | ||
| Q3 25 | $-1.01 | $0.75 | ||
| Q2 25 | $-0.98 | $0.78 | ||
| Q1 25 | $-0.86 | $1.00 | ||
| Q4 24 | — | $0.71 | ||
| Q3 24 | $-0.79 | $0.44 | ||
| Q2 24 | $-0.63 | $0.82 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $402.7M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $505.7M | $196.7M |
| Total Assets | $566.7M | $454.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $402.7M | $64.1M | ||
| Q3 25 | $305.1M | $104.1M | ||
| Q2 25 | $293.2M | $88.9M | ||
| Q1 25 | $321.4M | $88.9M | ||
| Q4 24 | $424.9M | $73.2M | ||
| Q3 24 | $501.9M | $80.1M | ||
| Q2 24 | $541.9M | $58.0M |
| Q1 26 | — | $196.7M | ||
| Q4 25 | $505.7M | $169.8M | ||
| Q3 25 | $369.0M | $155.3M | ||
| Q2 25 | $420.9M | $130.4M | ||
| Q1 25 | $469.7M | $125.8M | ||
| Q4 24 | $510.6M | $87.8M | ||
| Q3 24 | $552.9M | $61.1M | ||
| Q2 24 | $588.3M | $50.3M |
| Q1 26 | — | $454.3M | ||
| Q4 25 | $566.7M | $400.2M | ||
| Q3 25 | $424.0M | $367.0M | ||
| Q2 25 | $473.6M | $350.6M | ||
| Q1 25 | $515.7M | $298.1M | ||
| Q4 24 | $560.4M | $298.4M | ||
| Q3 24 | $604.0M | $252.9M | ||
| Q2 24 | $620.1M | $212.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.6M | — |
| Free Cash FlowOCF − Capex | $28.5M | — |
| FCF MarginFCF / Revenue | 33.5% | — |
| Capex IntensityCapex / Revenue | 0.1% | — |
| Cash ConversionOCF / Net Profit | 1.47× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-109.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $28.6M | $70.6M | ||
| Q3 25 | $-46.5M | $63.7M | ||
| Q2 25 | $-43.4M | $23.1M | ||
| Q1 25 | $-47.8M | $52.5M | ||
| Q4 24 | $-134.6M | $57.4M | ||
| Q3 24 | $-29.4M | $35.1M | ||
| Q2 24 | $-30.2M | $22.2M |
| Q1 26 | — | — | ||
| Q4 25 | $28.5M | $70.6M | ||
| Q3 25 | $-46.6M | $63.6M | ||
| Q2 25 | $-43.4M | $22.7M | ||
| Q1 25 | $-48.4M | $52.5M | ||
| Q4 24 | $-138.4M | $57.4M | ||
| Q3 24 | $-31.2M | $35.1M | ||
| Q2 24 | $-30.6M | $22.2M |
| Q1 26 | — | — | ||
| Q4 25 | 33.5% | 90.2% | ||
| Q3 25 | -51765.6% | 110.6% | ||
| Q2 25 | -289620.0% | 43.6% | ||
| Q1 25 | -345635.7% | 108.9% | ||
| Q4 24 | -13837100.0% | 118.5% | ||
| Q3 24 | -1038966.7% | 98.6% | ||
| Q2 24 | -611840.0% | 73.4% |
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 0.1% | ||
| Q3 25 | 101.1% | 0.3% | ||
| Q2 25 | 440.0% | 0.8% | ||
| Q1 25 | 4507.1% | 0.1% | ||
| Q4 24 | 378600.0% | 0.1% | ||
| Q3 24 | 59266.7% | 0.0% | ||
| Q2 24 | 6980.0% | 0.1% |
| Q1 26 | — | — | ||
| Q4 25 | 1.47× | 1.65× | ||
| Q3 25 | — | 2.39× | ||
| Q2 25 | — | 0.84× | ||
| Q1 25 | — | 1.45× | ||
| Q4 24 | — | 2.26× | ||
| Q3 24 | — | 2.27× | ||
| Q2 24 | — | 0.75× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
